2014-11-14T11:56:15-06:00 2013-12-31 KPMG LLP 60 South Street Boston MA 02111 990 2013-01-01 010211513 THE JACKSON LABORATORY % LINDA A JENSEN JACK 2072886000 600 MAIN STREET Suite BAR HARBOR ME 04609 LINDA JENSEN CFO 2072886000 2014-11-13 true TARA D'AGOSTINO P01245482 2072886000 2013 2015-11-30 17:44:51Z EDISON T LIU MD 600 MAIN STREET BAR HARBOR ME 04609 424488622 false X WWW.JAX.ORG X 1929 ME WE DISCOVER PRECISE GENOMIC SOLUTION FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. 22 20 1725 55 8226 -7733 67271113 74310661 159830571 161752623 2796712 15332676 1181585 5736826 231079981 257132786 0 17500 0 0 111935295 114591517 0 130573 2566268 91016891 101389780 202952186 216129370 28127795 41003416 527038278 612525781 176017760 195747777 351020518 416778004 X WE DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. false false 100095171 17500 161411153 DEVELOP AND PROVIDE GENETIC RESOURCES AND SERVICES - PLEASE SEE SCHEDULE O FOR DETAIL. 74456538 51116 BIOMEDICAL RESEARCH - PLEASE SEE SCHEDULE O FOR DETAIL. 6009556 539930 EDUCATION AND TRAINING - PLEASE SEE SCHEDULE O FOR DETAIL. 180561265 true true false true false false false false false true true true false false true true true false false true true false false true true false false true false true true true false false false false false false false true true true false false false false false false false false true 186 0 true 1725 true true true false false false false true true false false false false X 22 20 true false false false false false false true true false false true true true true true true true true false CA CT FL ME MA NY PA X X X LINDA A JENSEN 2072886108 600 MAIN STREET BAR HARBOR ME 04609 EDISON T LIU MD CHIEF EXECUTIVE OFFICER 40.0 X X 817268 0 129951 CHARLES E HEWETT PHD EXECUTIVE VICE PRESIDENT 40.0 X X 623521 0 293267 DAVID BALTIMORE PhD TRUSTEE 1.0 X 0 0 0 DAVID R CABOT TRUSTEE 1.0 X 0 0 0 KATHLEEN A CORBET TRUSTEE 1.0 X 0 0 0 LOUIS J D'AMBROSIO TRUSTEE 1.0 X 0 0 0 JEFFREY DUNN TRUSTEE 1.0 X 0 0 0 DAVID D ELLIMAN TRUSTEE 1.0 X 0 0 0 ANTHONY B EVNIN PhD TRUSTEE 1.0 X 0 0 0 JAMES J GALLOGLY TREASURER 1.0 X X 0 0 0 PETER F GERRITY SECRETARY 1.0 X X 0 0 0 RICHARD S GURIN TRUSTEE 1.0 X 0 0 0 LEO A HOLT CHAIR OF BOARD 1.0 X 0 0 0 WESLIE R JANEWAY VICE CHAIR OF BOARD 1.0 X 0 0 0 RICHARD S LANNAMANN TRUSTEE 1.0 X 0 0 0 SAM R LITTLE TRUSTEE 1.0 X 0 0 0 TOM MANIATIS TRUSTEE 1.0 X 0 0 0 NEAL B MILCH JD TRUSTEE 1.0 X 0 0 0 DENNIS PAUSTENBACH PhD TRUSTEE 1.0 X 0 0 0 CHARLES M RICE PhD TRUSTEE 1.0 X 0 0 0 DAVID J ROUX TRUSTEE 1.0 X 0 0 0 EDWARD RUBIN MD PhD TRUSTEE 1.0 X 0 0 0 DAVID VALLE MD TRUSTEE 1.0 X 0 0 0 THOMAS S VOLPE TRUSTEE 1.0 X 0 0 0 LINDA A JENSEN MS CHIEF FINANCIAL OFFICER 40.0 X 335519 0 54059 BRIAN R LESLIE GENERAL COUNSEL 40.0 X 306419 0 26602 JAY VETELINO ASSISTANT TREASURER 40.0 X 112036 0 35593 JANA ROBINSON ASSISTANT SECRETARY 40.0 X 70942 0 25627 ROBERT E BRAUN PHD VICE PRESIDENT RESEARCH 40.0 X 353963 0 36618 LEAH RAE B DONAHUE PHD DIR GENETIC RESOURCE SCIENCE 40.0 X 241062 0 49460 CHARLES LEE MD SCIENTIFIC DIRECTOR, JAX GM 37.0 X 186938 0 8798 AUROBINDO NAIR PHD GM SCIENTIFIC RESEARCH SVCS 40.0 X 345682 0 56789 KATHY L VANDEGRIFT ASSOCIATE GENERAL MANAGER 40.0 X 304982 0 45759 MICHAEL HYDE VP EXTERNAL AFFAIRS 40.0 X 327208 0 83195 JANAN T EPPIG PHD PROFESSOR 40.0 X 236828 0 43953 KRISTEN B ROZANSKY VP DEVELOPMENT & COMMUNICATION 40.0 X 240204 0 14664 YIJUN RUAN PHD DIRECTOR, JAX GM 40.0 X 324324 0 45564 LINDA WATERMAN DVM SR DIR LAB ANIMAL HEALTH 40.0 X 245566 0 25908 MICHAEL WATERS SR DIR OPPORTUNITY DEVELOPMENT 40.0 X 241443 0 43992 5313905 0 1019799 161 false true false CENTERBROOK ARCHITECT AND PLANNERS PO BOX 955 CENTERBROOK CT 06409 ARCHITECT 1930589 COLUMBUS IT PARTNER USA 750 WASHINGTON BLVD STAMFORD CT 06901 IT CONSULTING 1475647 GILBANE BUILDING COMPANY 7 JACKSON WALKWAY PROVIDENCE RI 02903 CONSTRUCTION MGMT 862770 DIGITAL CONSULTING SOFTWARE 2277 PLAZA DRIVE SUGARLAND TX 77479 IT CONSULTING 843243 FUSION CONSULTING INC 5215 N OCONNOR BLVD IRVING TX 75039 IT CONSULTING 551513 30 290410 63333388 10686863 512694 74310661 GENETIC RESOURCES 541700 161161577 161161577 TRAINING & EDUCATION 541700 539930 539930 RESEARCH 541700 51116 51116 161752623 1619662 8226 1611436 0 5576477 5576477 0 0 0 0 0 180967948 6050 166658329 602655 14309619 -596605 13713014 13713014 5625 290410 94852 -89227 -89227 0 0 0 OTHER REVENUE 900099 249576 249576 249576 257132786 162002199 8226 20811700 17500 17500 0 0 0 6048265 1264455 4783810 0 80317401 65988417 13129653 1199331 6383225 5676740 601908 104577 15643025 10737308 4734570 171147 6199601 5093564 1013462 92575 0 595361 7507 587854 344000 25000 319000 54596 54596 130573 130573 238384 238384 10169166 9022128 990390 156648 607491 553598 53893 2006977 1170368 761788 74821 5745062 4652210 1022513 70339 91918 91918 11694686 10653304 977719 63663 4617309 3476697 869675 270937 0 443322 370739 67893 4690 3251277 3133034 107383 10860 0 23069093 21702269 1263239 103585 1460359 1402810 52483 5066 OTHER SERVICES 1502876 1286940 210293 5643 STIPENDS 777476 777476 SUPPLIES 34073089 32958764 1024607 89718 EQUIPMENT RENTAL 464764 338978 124700 1086 182574 159541 12024 11009 216129370 180561265 33001837 2566268 25000 25000 127411597 121799993 7608605 6944458 16269357 18160263 0 0 0 0 1400000 400000 2113025 2534227 3745110 5116981 545181677 216149315 245584201 329032362 50547308 64791916 40207968 44173801 0 0 0 0 32126107 19546780 527038278 612525781 35361286 42712651 0 0 8529837 7289540 109371484 106014868 0 0 0 0 5262000 27720155 0 0 17493153 12010563 176017760 195747777 X 310202312 369076773 32170686 37321434 8647520 10379797 351020518 416778004 527038278 612525781 X 41003416 -2312903 27066973 X false true X true true true X 69040663 73823292 41644804 67271113 74310661 326090533 0 0 69040663 73823292 41644804 67271113 74310661 326090533 0 326090533 3370975 2954194 2311932 2888204 7196139 18721444 2274 44551 15206 62031 131000 18635 220423 225566 255201 850825 345724833 685166170 0.94321 0.95244 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 188554 false 188554 false LOBBYING ACTIVITY BY NON-ELECTING 501(C)(3) ORGANIZATION PART II-B, LINE 1G THE TOTAL LOBBYING EXPENSE FOR THE YEAR ENDED DECEMBER 31, 2013 WAS $188,554, WHICH WAS AN ALLOCATION OF EMPLOYEE COMPENSATION FOR LOBBYING ACTIVITIES AND $10,000 FOR AN ENGAGEMENT WITH THE PETRIZZO GROUP INC., OF WASHINGTON DC TO ARRANGE INTRODUCTIONS WITH PROGRAM OFFICERS IN VARIOUS FEDERAL AGENCIES. 90755276 6074191 13007247 870995 108965719 80841065 1280959 9091700 458448 90755276 87452850 74725 -5827854 858656 80841065 74765000 2345649 10790669 448468 87452850 58922000 6051000 10277000 485000 74765000 0.62000 0.09000 0.29000 false false 6294126 6294126 331273188 146062797 185210391 106639038 70086518 36552520 100975325 100975325 329032362 US EQUITY 16768433 F INTERNATIONAL EQUITY 11422552 F ALTERNATIVE 15982816 F 44173801 0 RETIREMENT PLAN OBLIGATIONS 6663241 INTEREST RATE SWAP 5347322 12010563 X 281678487 -2312903 4250 27064973 24756320 256922167 305471 -94852 210619 257132786 215921001 4250 94852 99102 215821899 305471 2000 307471 216129370 ENDOWMENT FUNDS PART V, LINE 4 THE INVESTMENT AND SPENDING POLICIES FOR THE ENDOWMENT ASSETS HAVE BEEN ESTABLISHED TO PROVIDE A PREDICTABLE STREAM OF FUNDING FOR THE PROGRAMS SUPPORTED BY ENDOWMENT INCOME, WHILE SEEKING TO MAINTAIN THE PURCHASING POWER OF THE ENDOWMENT ASSETS. IN ADDITION, WHEN CONSIDERING THE AMOUNT OF INCOME TO APPROPRIATE FROM BOARD-DESIGNATED ASSETS, THE TRUSTEES CONSIDER THE NEED TO MAINTAIN UNRESTRICTED ASSETS TO MEET LIQUIDITY COVENANTS RELATED TO OUTSTANDING BONDS. ACCORDINGLY, THE BOARD OF TRUSTEES HAS SET THE INVESTMENT ALLOCATION TO ACHIEVE A NOMINAL RATE OF RETURN THAT WILL AT LEAST COVER INFLATION AND THE SPEND RATE WITH A PRUDENT LEVEL OF RISK. THE INVESTMENT ALLOCATION FOR THE BOARD-DESIGNATED PORTION OF THE ENDOWMENT IS SET TO ACHIEVE GREATER STABILITY IN THE VALUE OF INVESTMENTS. THE BOARD ALLOCATED 4% OF THE THREE YEAR AVERAGE VALUE OF DONOR-DESIGNATED ENDOWMENT BALANCES TO SUPPORT THE DESIGNATED PROGRAMS. ALL EARNINGS ON DONOR ENDOWMENTS ESTABLISHED TO PROVIDE GENERAL SUPPORT FOR THE LABORATORY AS APPROVED BY THE BOARD OF TRUSTEES WERE RETAINED IN THE ENDOWMENT. THE BOARD OF TRUSTEES WISHES TO INCREASE THE AMOUNT OF ENDOWMENT SUPPORT AVAILABLE IN THE FUTURE. LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) PART X, LINE 2 THE LABORATORY IS A NOT-FOR-PROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE CODE), AS AMENDED, AND IS GENERALLY EXEMPT FROM INCOME TAXES PURSUANT TO THE CODE. IN ACCORDANCE WITH GAAP, THE LABORATORY ASSESSES WHETHER THERE ARE UNCERTAIN TAX POSITIONS AND DETERMINED THERE WERE NO UNCERTAIN TAX POSITIONS THAT WOULD HAVE A MATERIAL EFFECT ON THE FINANCIAL STATEMENTS. OTHER REVENUE ON FINANCIAL STATEMENTS NOT ON RETURN PART XI, LINE 2D UNREALIZED GAINS ON INTEREST RATE SWAPS 3,649,266 CHANGES IN ACTUARIAL ASSUMPTIONS 798,400 FAIR MARKET VALUE ADJUSTMENT ON LOANS 22,619,307 INCOME TAX EXPENSES NETTED IN REVENUE (2,000) TOTAL 27,064,973 OTHER REVENUE ON RETURN NOT IN FINANCIAL STATEMENTS PART XI, LINE 4B RECLASS OF FUNDRAISING EXPENSES (94,852) OTHER EXPENSES INCLUDED IN FINANCIAL STATEMENT NOT ON RETURN PART XII, LINE 2D RECLASS OF FUNDRAISING EXPENSES 94,852 OTHER EXPENSE ON RETURN NOT ON FINANCIAL STATEMENT PART XII, LINE 4B INCOME TAX EXPENSES NETTED IN REVENUE 2,000 Europe (Including Iceland and Greenland) 1 Program Services RESEARCH 133441 Central America and the Caribbean Investments 23955720 East Asia and the Pacific Program Services RESEARCH 13500 Central America and the Caribbean Program Services GENETIC RESOURCES 0 East Asia and the Pacific Program Services GENETIC RESOURCES 0 Europe (Including Iceland and Greenland) Program Services GENETIC RESOURCES 0 Middle East and North Africa Program Services GENETIC RESOURCES 0 North America Program Services GENETIC RESOURCES 0 Russia and the Newly Independent States Program Services GENETIC RESOURCES 0 South America Program Services GENETIC RESOURCES 0 South Asia Program Services GENETIC RESOURCES 0 Sub-Saharan Africa Program Services GENETIC RESOURCES 0 1 1 24102661 24102661 true false true false true true X X X X X X X true GRENZEBACH GLIER ASSOC 401 N MIC 401 N MICHIGAN AVENUE SUITE 2800 CHICAGO IL 60611 STR CONSULT FUNDRAISING false 130573 -130573 130573 -130573 CA CT FL ME MA NY PA DISCOVERY DAYS 133575 127950 5625 79792 PORTLAND LUNCH 104825 104825 9507 10 57635 57635 5553 296035 290410 5625 94852 94852 -89227 true CONNECTICUT UNITED FOR RESEARCH EXCELLENCE 350 CHURCH STREET HARTFORD CT 06103 061304212 501(C)(3) 12500 SUPPORT 1 0 MONITOR THE USE OF GRANT FUNDS PART I, LINE 2 THE ALLOCATION OF GRANTS AND OTHER ASSISTANCE TO LOCAL ORGANIZATIONS IS DETERMINED ON AN ANNUAL BASIS. X true true X X X X X true true false false false false false true false EDISON T LIU MD CHIEF EXECUTIVE OFFICER 748616 0 50000 0 18652 0 103500 0 26451 0 947219 0 0 0 CHARLES E HEWETT PHD EXECUTIVE VICE PRESIDENT 536069 0 50000 0 37452 0 268500 0 24767 0 916788 0 0 0 LINDA A JENSEN MS CHIEF FINANCIAL OFFICER 281833 0 40000 0 13686 0 25500 0 28559 0 389578 0 0 0 BRIAN R LESLIE GENERAL COUNSEL 265872 0 0 40547 0 10938 0 15664 0 333021 0 0 0 JANAN T EPPIG PHD PROFESSOR 236828 0 0 0 0 0 23572 0 20381 0 280781 0 0 0 KRISTEN B ROZANSKY VP DEVELOPMENT & COMMUNICATION 195737 0 0 0 44467 0 1231 0 13433 0 254868 0 0 0 YIJUN RUAN PHD DIRECTOR, JAX GM 312287 0 0 0 12037 0 21593 0 23971 0 369888 0 0 0 LINDA WATERMAN DVM SR DIR LAB ANIMAL HEALTH 202359 0 38900 0 4307 0 16535 0 9373 0 271474 0 0 0 MICHAEL WATERS SR DIR OPPORTUNITY DEVELOPMENT 196436 0 28051 0 16956 0 19086 0 24906 0 285435 0 0 0 ROBERT E BRAUN PHD VICE PRESIDENT RESEARCH 318577 0 10000 0 25386 0 25500 0 11118 0 390581 0 0 0 LEAH RAE B DONAHUE PHD DIR GENETIC RESOURCE SCIENCE 186474 0 30000 0 24588 0 20249 0 29211 0 290522 0 0 0 CHARLES LEE MD SCIENTIFIC DIRECTOR, JAX GM 118077 0 0 0 68861 0 0 0 8798 0 195736 0 0 0 AUROBINDO NAIR PHD GM SCIENTIFIC RESEARCH SVCS 268594 0 65381 0 11707 0 25500 0 31289 0 402471 0 0 0 KATHY L VANDEGRIFT ASSOCIATE GENERAL MANAGER 241070 0 57949 0 5963 0 22472 0 23287 0 350741 0 0 0 MICHAEL HYDE VP EXTERNAL AFFAIRS 265679 0 35000 0 26529 0 38500 0 44695 0 410403 0 0 0 BENEFITS PART I, LINE 1A TAX INDEMNIFICATION AND GROSS-UP PAYMENTS: THE JACKSON LABORATORY GROSSES UP THE AMOUNT ADDED TO WAGES FOR IMPUTED INSURANCE PREMIUMS FOR THE SENIOR MANAGEMENT GROUP TO COVER TAXES. THE LABORATORY ALSO GROSSES UP WAGES TO COVER THE TAX IMPACT OF GIFT CARDS AND OTHER AWARDS OR PRIZES TO EMPLOYEES SO THAT THE RECIPIENTS RECEIVE THE FULL VALUE OF THE GIFT OR AWARD. SEVERANCE PAYMENT PART I, LINE 4A THE JACKSON LABORATORY PAID SEVERANCE OF $9,806 TO THE SENIOR DIRECTOR OF OPPORTUNITY DEVELOPMENT DURING THE YEAR. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B THE LABORATORY MAINTAINS A DEFERRED COMPENSATION PLAN UNDER SECTION 457(F). THE PRESIDENT/CEO AND EXECUTIVE VICE PRESIDENT/COO PARTICIPATE IN A NON-QUALIFIED SUPPLEMENTAL RETIREMENT PLAN THAT PROVIDES FOR A PORTION OF THEIR COMPENSATION TO BE DEFERRED UNDER A SECTION 457 (F) PLAN. THE PRESIDENT/CEO DEFERRED $78,000 AND THE EXECUTIVE VICE PRESIDENT/COO DEFERRED $75,000 UNDER THIS PLAN DURING CALENDAR YEAR 2013. NON-FIXED PAYMENTS PART I, LINE 7 THE TOTAL COMPENSATION PACKAGE OF CERTAIN OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES INCLUDES VARIABLE COMPENSATION AWARDED BASED ON PERFORMANCE. A ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CLX6 2007-09-12 35075000 FINANCE CONSTRUCTION & REFUND true false false B FINANCE AUTHORITY OF MAINE 042456011 2012-08-31 42460000 REFUND false false false C ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CTH3 2012-10-24 66355769 FINANCE CONSTRUCTION & REFUND A 275000 32750000 35075000 0 1004292 0 456682 0 0 31597588 2016438 0 2009 true false true true B 1735000 0 42460000 0 0 0 0 0 0 0 42460000 0 2002 true false true true C 990000 0 66432099 0 0 37252968 623401 0 0 26665257 1890473 0 2014 false true false true A false false true true true true 0.01107 0.00000 0.01107 false false 0.00000 false false B false false false true true 0.00072 0.00000 0.00072 false false 0.00000 false false C false false true true true true 0.01212 0.00000 0.01212 false false 0.00000 false false A false false false true false false 0 false 0 false false B false false false true true false 0 false 0 false false C false true false false false false 0 false 0 false false A true B true C true BOND PROCEEDS - BOND ISSUE C PART II, LINE 3 THE DIFFERENCE IN ISSUE PRICE AND LINE 3 PROCEEDS FOR BOND ISSUE C IS INTEREST INCOME FROM THE AMOUNTS HELD IN THE REFUNDING ESCROW ACCOUNT. PART IV, LINE 2(C) BOND ISSUE A - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 10/03/13 BY AMTEC (REFLECTING ACTIVITY THROUGH 08/31/13). BOND ISSUE B - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 01/23/14 BY AMTEC (REFLECTING ACTIVITY THROUGH 10/31/13). BANGOR SAVINGS BANK OFFICER - CHARLES HEWETT 1144974 CREDIT CARD PROCESSING FEES false MADELEINE BRAUN PHD KEY EMPLOYEE-ROBERT BRAUN 142660 EMPLOYMENT - FAMILY MEMBER false X 24 462916 FMV X CATERING SUPPLIES 4 49778 FMV (INVOICES) 0 false true false CONTRIBUTIONS PART I, COLUMN B THE NUMBER OF CONTRIBUTIONS ARE REPORTED IN COLUMN B. ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS TO DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. TO ACCOMPLISH THIS MISSION THE LABORATORY 1) CONDUCTS BASIC BIOMEDICAL RESEARCH TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGICAL, AND GENETICALLY DETERMINED AILMENTS THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL ANIMALS; 2) CONDUCTS TRANSLATIONAL BIOMEDICAL RESEARCH TO IDENTIFY THE GENOMIC BASIS FOR HUMAN DISEASE, PROMOTE THE ESTABLISHMENT OF MORE PRECISE, TARGETED THERAPIES, AND OFFER CUTTING EDGE GENOMIC DIAGNOSTICS TO THE MEDICAL COMMUNITY; 3) TRAINS AND EDUCATES SCIENTISTS, PHYSICIANS, AND OTHER PROFESSIONALS IN THESE AREAS; AND 4) PROMOTES SCIENTIFIC DISCOVERY THROUGH THE PROVISION OF MOUSE MODELS OF HUMAN DISEASE AND THE PROVISION OF RESEARCH AND CLINICAL SERVICES TO THE GLOBAL SCIENTIFIC AND MEDICAL COMMUNITY. THE LABORATORY ALSO WORKS TO ACCELERATE THE TRANSLATION OF DISCOVERIES MADE IN BASIC RESEARCH TO TREATMENTS FOR HUMAN DISEASE. PROGRAM SERVICES FORM 990, PART III, LINE 4A-4C 4A. GENETIC RESOURCES AND SERVICES ACCOMPLISHMENTS JAX PROVIDES THE SCIENTIFIC COMMUNITY WITH MOUSE GENETIC RESOURCES, RELATED TECHNOLOGIES, AND INFORMATION THAT SUPPORTS THEIR USE. THIS INCLUDES CONDUCTING PEER-REVIEWED, RESOURCE-GENERATING RESEARCH AND MANAGING THE MOUSE REPOSITORY, A COLLECTION OF NEARLY 7,000 UNIQUE STRAINS, MANY OF WHICH ARE AVAILABLE ONLY FROM JAX. JAX DEVELOPS MOUSE MODELS FOR HUMAN DISEASE, BEGINNING WITH DISCOVERIES OF SPONTANEOUS MUTANTS FROM JAX PRODUCTION COLONIES AND INCLUDING THE OPTIMIZATION OF MODELS ACQUIRED BY THE REPOSITORY. THIS EFFORT INCLUDES ENGINEERING NEW MODELS FOR OUR OWN HYPOTHESIS-DRIVEN RESEARCH. DURING 2013 THE LABORATORY WORKED ON 74 PROJECTS (34 TARGETED, 40 TRANSGENIC) TO CREATE MODELS FOR ALS, BIM1, CMAH DEFICIENCY, DRAVET SYNDROME, OROFACIAL-CLEFTING, MPS1, PARKINSON'S DISEASE, RETT SYNDROME, AND X-LINKED SMA. JAX HAS PILOT STUDIES TO HUMANIZE LARGE SEGMENTS OF THE MOUSE GENOME (10S TO 100S OF KILOBASE PAIRS, KBP). MODELING A DISEASE-RELATED DELETION POLYMORPHISM WITHIN A HUMAN LEUKEMIA GENE AS A TEST CASE, JAX SCIENTISTS ARE MOVING A 25-KBP SEGMENT OF HUMAN DNA INTO THE MOUSE GENOME USING THREE METHODS. METHOD I HARNESSES HOMOLOGOUS RECOMBINATION (HR), THE NATURAL BIOLOGICAL PROCESS BY WHICH CELLS REPAIR DNA DAMAGE. METHOD II MAKES USE OF CERTAIN ENZYMES (FOUND IN BAKER'S YEAST AND PARTICULAR BACTERIAL VIRUSES) THAT ARE CAPABLE OF SITE-SPECIFIC RECOMBINATION (SSR). METHOD III, A POTENTIAL JAX INNOVATION, WILL ATTEMPT TO TRIGGER RECOMBINATION USING SHORT, LINEAR DNA BRIDGING MOLECULES (DNAB). NO MATTER THE METHOD, EACH APPROACH AIMS TO PLACE HUMAN DNA INTO THE LARGER MOUSE GENOMIC CONTEXT; FIRST, WITHIN A BACTERIAL CARRIER; NEXT, IN MOUSE EMBRYONIC STEM CELLS; AND ULTIMATELY, IN LIVE MOUSE STRAINS. ONCE EXPANDED TO INCLUDE OTHER CANCER-RELATED GENES, THE BROADER GOAL IS TO PROVIDE A PUBLIC SCIENTIFIC RESOURCE FOR THE STUDY OF THE HEALTHY/PATHOLOGICAL ACTIVITIES OF HUMAN GENES AND THE DEVELOPMENT OF THERAPEUTICS, IN A WHOLE ANIMAL CONTEXT. THE MOUSE MUTANT RESOURCE (MMR) IS THE JACKSON LABORATORY'S PRIMARY REPOSITORY FOR THE ACQUISITION AND CHARACTERIZATION OF MICE CARRYING SPONTANEOUS, DISEASE-CAUSING MUTATIONS. A PRIMARY GOAL FOR THE MMR OVER THE PAST YEAR WAS TO INCREASE THE RATE OF IDENTIFYING CAUSATIVE MUTATIONS IN MMR STRAINS USING THE LATEST GENOMIC TECHNOLOGIES. THE NUMBER OF CAUSATIVE MUTATIONS IDENTIFIED IN THE MMR WAS 21 THROUGH THE FIRST HALF OF 2013. AS AN EXAMPLE, A MUTANT STRAIN OF SPECIAL INTEREST THIS YEAR IS "JAGGED TAIL LIKE" (JGL). THE JGL IS A SPONTANEOUS, RECESSIVE MUTATION THAT AROSE IN BALB/CBYJ. AFFECTED MALE MICE ARE INFERTILE DUE TO GERM CELL DEPLETION AND BOTH SEXES HAVE MILD SKELETAL DEFECTS. THE MUTATION WAS MAPPED TO A ~12 MB REGION ON CHROMOSOME 5 AND EXOME SEQUENCING REVEALED A NONSENSE MUTATION IN KNTC1 (KINETOCHORE ASSOCIATED 1), WHICH ENCODES THE MAMMALIAN HOMOLOG OF ROD, A PROTEIN THAT IS PART OF THE KINETOCHORE AND IS REQUIRED FOR RECRUITMENT OF DYNEIN. THIS IS THE FIRST REPORTED MOUSE MUTATION IN THIS GENE. A SECOND NOTABLE NOVEL STRAIN DISCOVERY THIS YEAR IS NEW MUTANT 3579. THIS RECESSIVE SPONTANEOUS MUTATION CAUSES NEUROLOGICAL, METABOLIC AND SKIN PHENOTYPES THAT ARE SIMILAR TO CUTIS-LAXA. EXOME SEQUENCING REVEALED A MUTATION IN PYCR2, WHICH IS ONE OF THREE GENES NECESSARY FOR PROLINE BIOSYNTHESIS. ROB BURGESS' LABORATORY, IN COLLABORATION WITH MMR STAFF, RECENTLY SUBMITTED A MANUSCRIPT ON THIS NOVEL STRAIN, ENTITLED "PYCR2 MUTATIONS LEAD TO MILD NEUROPATHY, SKIN PHENOTYPES, AND METABOLIC CHANGES IN MICE". THIS IS THE FIRST REPORT OF A MOUSE MUTATION IN PYCR2, AS WELL AS THE FIRST REPORT ASSOCIATING PYCR2 WITH CUTIS-LAXA. WHILE JAX DEVELOPS NEW MOUSE MODELS IN HOUSE, THE REPOSITORY'S MAJOR SOURCE OF NEW MOUSE STRAINS IS THE STRAIN ACQUISITION PROGRAM. ACQUISITION ADDED APPROXIMATELY 600 STRAINS IN 2013, INCREASING THE SIZE OF THE JAX COLLECTION TO >7,250 INDIVIDUAL MOUSE LINES. A KEY COMPONENT OF THE ACQUISITION PROCESS IS THE WORK DONE BY A TEAM OF CURATORS WHO ARE RESPONSIBLE FOR INTERACTING WITH DONATING LABORATORIES TO OBTAIN TECHNICAL INFORMATION AND ARRANGE IMPORTATION. CURATORS ASSIMILATE INFORMATION FROM DONATING RESEARCHERS AND PUBLISHED LITERATURE TO COMPOSE A "USER MANUAL" FOR EACH LINE. THIS INFORMATION IS ADDED TO THE JAXMICE CATALOGUE FOR USE BY THE SCIENTIFIC COMMUNITY. JAX OFFERS ONE OF THE MOST EXTENSIVE AND DIVERSE MOUSE RESOURCES IN EXISTENCE, ALLOWING US TO SUPPORT A WIDE ARRAY OF RESEARCH AND TO PRESERVE STRAINS THAT OTHERWISE MIGHT BE LOST. THE JAX CRE REPOSITORY IS AN INTEGRATED EFFORT TO GENERATE, CHARACTERIZE AND DISTRIBUTE CRE DRIVER TOOL STRAINS TO THE SCIENTIFIC COMMUNITY. THESE STRAINS ALLOW SCIENTISTS TO GENERATE PRECISE GENE DELETIONS IN A SPECIFIC ORGAN AT A SPECIFIC TIME. THE JAX CRE REPOSITORY CURRENTLY COMPRISES OVER 300 OF THESE STRAINS THAT COMPLEMENT OUR COLLECTION OF >500 "KNOCKOUT READY" STRAINS. WE EMPLOY A COMPREHENSIVE, HIGH-THROUGHPUT CRE DRIVER STRAIN CHARACTERIZATION PIPELINE, WHICH INCLUDES TWO EMBRYONIC AND TWO POSTNATAL TIME POINTS, TO PROVIDE EXTENDED FUNCTIONAL DATA FOR END USERS. ALL IMAGE AND ANNOTATION DATA IS AVAILABLE THROUGH OUR WEBSITE AND A NEW DATABASE DEVELOPED BY MOUSE GENOME INFORMATICS (MGI) AT JAX, CREPORTAL.ORG. THE CRE REPOSITORY WEBSITE IS ONE OF THE MOST HEAVILY VISITED SECTIONS OF ALL JAX WEBSITES, WITH OVER 120,000 PAGEVIEWS PER YEAR. CHARACTERIZATION DATA WEBPAGES SEE ESPECIALLY HEAVY TRAFFIC, DEMONSTRATING THAT THIS VALUE-ADDED INFORMATION IS BEING ACTIVELY EMPLOYED BY CRE MOUSE USERS. A MAJORITY OF THE STRAINS PRODUCED BY THE KNOCKOUT MOUSE PROJECT (KOMP2) AND INTERNATIONAL PHENOTYPING PROGRAMS CAN BE MODIFIED BY CRE TOOL STRAINS, SO THE LABORATORY IS WORKING TO ALIGN THE JAX CRE REPOSITORY WITH THIS EFFORT. TWO PROJECTS TOWARDS THIS END ARE UNDERWAY. THE FIRST LEVERAGES THE CAPACITY OF THE JAX KOMP2 PHENOTYPING CENTER TO DETERMINE IF POPULAR CRE STRAINS DISPLAY POTENTIALLY CONFOUNDING PHENOTYPES. THIS SET OF STRAINS COMPRISES THOSE WITH HIGH DISTRIBUTION HISTORY AND OTHERS OF SPECIFIC INTEREST. TEN STRAINS HAVE COMPLETED TESTING AND DATA ANALYSIS IS UNDERWAY. THE SECOND PROJECT IS BACKCROSSING AN OVERLAPPING SET TO C57BL/6NJ, PROVIDING A COMPLEMENTARY RESOURCE ON THE SAME GENETIC BACKGROUND AS THE KOMP2 RESOURCE. SIXTEEN STRAINS ARE IN PROGRESS,AND ARE 86%-100% CONGENIC ON THE C57BL/6NJ BACKGROUND, INCLUDING FIVE THAT ARE COMPLETE AND BEING REDERIVED INTO THE REPOSITORY FOR DISTRIBUTION. AS PART OF OUR FACEBASE CONSORTIUM PROJECT, WE ARE GENERATING 15 CRE DRIVER LINES FOR THE CRANIOFACIAL RESEARCH COMMUNITY OVER FIVE YEARS AND WILL BE THE REPOSITORY FOR THESE AND OTHER MODELS GENERATED BY THE CONSORTIUM. THESE STRAINS WILL ALLOW OTHER INVESTIGATORS TO DELETE GENES IN SPECIFIC PARTS OF THE DEVELOPING FACE AND PALATE, ALLOWING DEEPER UNDERSTANDING OF THE GENETIC MECHANISMS OF THESE BIRTH DEFECTS. FOUR NEW CRE DRIVER STRAINS ARE CHARACTERIZED AND PUBLICLY AVAILABLE, AND SEVERAL MORE (BOTH KNOCK-IN AND TRANSGENIC ALLELES) WILL BE PUBLIC THIS YEAR. OUR CHARACTERIZATION SCHEME BUILDS UPON THE PLATFORM DESCRIBED ABOVE AND INCORPORATES ADDITIONAL TIME POINTS AND TISSUES SPECIFIC TO THE TARGET STRUCTURES. OVERALL, THIS PROJECT PROVIDES A MODEL FOR ADDITIONAL CRE DRIVER STRAIN PROJECTS TO ADD TO THE OVERALL CRE REPOSITORY. KNOCKOUT MOUSE PROJECT (KOMP) - JAX DEVELOPED AN EXTENSIVE GENE TARGET LIST OF 1168 GENES WITH RECOMMENDATIONS FROM NEARLY ALL OF THE JAX FACULTY AND A NUMBER OF EXTERNAL COLLABORATORS. THE GENE LIST WAS ASSEMBLED TO SERVE THE STRATEGIC INTERESTS OF NUMEROUS RESEARCH PROGRAMS, AND ALLOWS US TO FOCUS ON GENERATING MICE WITH GENE DELETIONS THAT WILL BE OF IMMEDIATE INTEREST TO RESEARCHERS. KOMP PARTNERS AROUND THE WORLD COORDINATED CLOSELY WITH EACH OTHER ON THE PROGRAM'S OVERALL TARGETED GENE LIST, TO MAXIMIZE IMPACT WHILE MINIMIZING DUPLICATION OF EFFORT. AN ESSENTIAL PART OF THE KOMP PROGRAM IS TO DEVELOP NEW TECHNOLOGIES AND APPROACHES THAT REDUCE COSTS, SPEED DELIVERY OF STRAINS AND IMPROVE THE ULTIMATE IMPACT OF THE PROJECT. IN COLLABORATION WITH LABORATORY, KOMP HAS HELPED VALIDATE THE "PERFECT HOST" STERILE BLASTOCYST TECHNOLOGY THROUGH SIDE-BY-SIDE COMPARISONS WITH KOMP CLONES. BASED ON THESE SUCCESSES, WE HAVE BEGUN PRODUCTION SCALE USE OF THE PERFECT HOST FOR KOMP OPERATIONS. TO REDUCE THE ENORMOUS COST OF SCREENING MICE FOR GERMLINE TRANSMISSION, WE HAVE EMPLOYED "ZINC FINGER NUCLEASE" (ZFN) TECHNOLOGY TO GENERATE AN ALBINO VERSION OF THE C57BL/6NJ STRAIN. THE RARE AND ORPHAN DISEASE CENTER - (RODC) BRINGS TOGETHER GLOBAL MOUSE RESOURCES AND THE EXPERTISE OF SCIENTISTS AT THE JACKSON LABORATORY TO ACCELERATE RESEARCH AND DRUG DISCOVERY FOR RARE AND ORPHAN DISEASES. WE PARTNER WITH FOUNDATIONS, PHARMACEUTICAL AND BIOTECH COMPANIES, AND OTHER SCIENTISTS WORLDWIDE TO FACILITATE RESEARCH INTO TREATMENTS OF THESE LESS COMMON DISEASES. WE ENGINEER NEW MODELS AND ENHANCE EXISTING MODELS THROUGH GENETIC STANDARDIZATION AN FORM 990 REVIEW PROCESS FORM 990, PART VI, SECTION B, QUESTION 11A THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER REVIEW, THE IRS FORM 990 IS FINALIZED AND PROVIDED TO THE BOARD OF TRUSTEES FOR THEIR REVIEW THEN IT IS FILED. CONFLICT OF INTEREST POLICY FORM 990, PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE FORMS AS WELL AS THE DISTRIBUTION OF ALL POLICIES REGARDING THE CONFLICT OF INTEREST AND CODE OF ETHICS. THIS PROCESS IS DONE ANNUALLY. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO THE GENERAL COUNSEL, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. DISCLOSURES, AS WELL AS ANY FOLLOW UP QUESTIONS, ARE ROUTED THROUGH GENERAL COUNSEL, AND IF NECESSARY THE AUDIT COMMITTEE. COMPENSATION POLICY FORM 990, PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOURCES COMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE VICE PRESIDENT OF RESEARCH, THE VICE PRESIDENT OF EXTERNAL AFFAIRS AND STRATEGIC PARTNERSHIPS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS' OR 'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SACTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. PUBLIC DISCLOSURE FORM 990, PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE WWW.JAX.ORG. THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE WWW.JAX.ORG. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 UNREALIZED GAINS ON INTEREST RATE SWAPS 3,649,266 CHANGES IN ACTUARIAL ASSUMPTIONS 798,400 FAIR MARKET VALUE ADJUSTMENT ON LOANS 22,619,307 TOTAL 27,066,973 SECURED MORTGAGES AND NOTES PAYABLE FORM 990, PART X, LINE 23 REPAYMENT TERMS THE CT INNOVATIONS LOANS WILL BE FORGIVEN IF AND WHEN THE LABORATORY MEETS AN EMPLOYMENT GOAL OF AT LEAST 300 EMPLOYEES LOCATED IN CONNECTICUT FOR A PERIOD OF SIX MONTHS, INCLUDING A MINIMUM OF 90 SENIOR SCIENTISTS. IN ADDITION, THE AVERAGE WAGE FOR SUCH EMPLOYEES MUST EXCEED A MINIMUM TARGET LEVEL.